Breast density reduction with linzagolix or bilastine in premenopausal women at high risk of breast cancer: a phase II clinical trial.
Sponsor: Consorci Mar Parc De Salut De Barcelona
Phase: 2
Disease: Breast cancer
EU trial number: 2026-525672-26-01
Population: Premenopausal women aged 35–50 years with high mammographic density and an estimated 5-year breast cancer risk of at least 1.67% by the Gail model, with regular menstrual cycles or hormone levels consistent with normal ovarian function.
Register Investigator Interest
Interested in offering this trial to suitable patients?